Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Tough-to-Treat lung cancer: experimental drug targets specific mutation

NCT ID NCT05445843

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing an experimental drug called JDQ443 as the first treatment for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The trial will enroll 95 participants to see how well the drug shrinks tumors and how safe it is. Researchers are particularly interested in patients whose tumors have certain other genetic features that might make them less responsive to standard treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC KRAS G12C-MUTATED NSCLC WITH A PD-L1 EXPRESSION <1% OR A PD-L1 EXPRESSION ≥ 1% AND AN STK11 CO-MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Pilar, Buenos Aires, B1629AHJ, Argentina

  • Novartis Investigative Site

    Buenos Aires, C1426AGE, Argentina

  • Novartis Investigative Site

    Córdoba, X5000JHQ, Argentina

  • Novartis Investigative Site

    Córdoba, X5016KEH, Argentina

  • Novartis Investigative Site

    Feldkirch, A 6807, Austria

  • Novartis Investigative Site

    Wels, A-4600, Austria

  • Novartis Investigative Site

    Sint-Niklaas, Oost Vlaanderen, 9100, Belgium

  • Novartis Investigative Site

    Roeselare, West-Vlaanderen, 8800, Belgium

  • Novartis Investigative Site

    Salvador, Estado de Bahia, 41825-010, Brazil

  • Novartis Investigative Site

    Belo Horizonte, 30360 680, Brazil

  • Novartis Investigative Site

    Rio de Janeiro, 22271-110, Brazil

  • Novartis Investigative Site

    Wuhan, Hubei, 430030, China

  • Novartis Investigative Site

    Changsha, Hunan, 410013, China

  • Novartis Investigative Site

    Beijing, 100036, China

  • Novartis Investigative Site

    Marseille, Bouches Du Rhone, 13915, France

  • Novartis Investigative Site

    Bron, 69677, France

  • Novartis Investigative Site

    Montpellier, 34070, France

  • Novartis Investigative Site

    Saint-Herblain, 44805, France

  • Novartis Investigative Site

    Strasbourg, 67091, France

  • Novartis Investigative Site

    Kempten (Allgäu), Bavaria, 87439, Germany

  • Novartis Investigative Site

    Halle, Saxony-Anhalt, 06120, Germany

  • Novartis Investigative Site

    Hamburg, 21075, Germany

  • Novartis Investigative Site

    Oldenburg, 26121, Germany

  • Novartis Investigative Site

    Tübingen, 72076, Germany

  • Novartis Investigative Site

    Athens, 11526, Greece

  • Novartis Investigative Site

    Mátraháza, 3200, Hungary

  • Novartis Investigative Site

    Thellakom Kottayam, Kerala, 686016, India

  • Novartis Investigative Site

    Varanasi, Uttar Pradesh, 221005, India

  • Novartis Investigative Site

    Bari, BA, 70124, Italy

  • Novartis Investigative Site

    Rozzano, MI, 20089, Italy

  • Novartis Investigative Site

    Roma, RM, 00128, Italy

  • Novartis Investigative Site

    Orbassano, TO, 10043, Italy

  • Novartis Investigative Site

    George Town, Pulau Pinang, 10450, Malaysia

  • Novartis Investigative Site

    Kuching, Sarawak, 93586, Malaysia

  • Novartis Investigative Site

    Breda, North Brabant, 4818 CK, Netherlands

  • Novartis Investigative Site

    Leeuwarden, Provincie Friesland, 8934 AD, Netherlands

  • Novartis Investigative Site

    Porto, 4100-180, Portugal

  • Novartis Investigative Site

    Barcelona, 08035, Spain

  • Novartis Investigative Site

    Madrid, 28041, Spain

  • Novartis Investigative Site

    Bangkok, 10700, Thailand

  • Novartis Investigative Site

    Istanbul, Bagcilar, 34214, Turkey (Türkiye)

  • Novartis Investigative Site

    Diyarbakır, Sur, 21280, Turkey (Türkiye)

  • Novartis Investigative Site

    Ankara, Yenimahalle, 06500, Turkey (Türkiye)

  • Novartis Investigative Site

    Torquay, TQ2 7AA, United Kingdom

  • The Brown University Oncology Group

    Providence, Rhode Island, 02903, United States

Conditions

Explore the condition pages connected to this study.

LOCALLY ADVANCED OR METASTATIC KRAS G12C-MUTATED NSCLC WITH A PD-L1 EXPRESSION <1% OR A PD-L1 EXPRESSION ≥ 1% AND AN STK11 CO-MUTATION